Novel Approaches to Diagnosing and Treating Generalized Pustular Psoriasis - Episode 11

Future Directions for GPP Management and Key Takeaways

Published on: March 29, 2025

Aaron Farberg, MD, FAAD , Harrison Nguyen, MD, MBA, MPH, FAAD , Boni Elewski, MD, FAAD , Johann Gudjonsson, MD, PhD, FAAD

Panelists discuss spesolimab’s place in therapy for treating generalized pustular psoriasis (GPP), address remaining unmet treatment needs, and share the types of future data they would like to see, along with key takeaways and advice for dermatologists managing patients with GPP.

Video content above is prompted by the following:

EP. 1: Clinical Presentation and Burden of Disease of Generalized Pustular Psoriasis

EP. 2: Impact of GPP Triggers and Flares on a Patient’s Physical and Mental Health

EP. 3: Approaches to Diagnosing GPP and Distinguishing It From Other Psoriatic Conditions

EP. 4: Challenges for Making a Timely GPP Diagnosis

EP. 5: GPP Pathogenesis and Treatment Goals

EP. 6: Older Treatment Approaches to GPP Management

EP. 7: Addressing the Psychosocial Aspects of GPP Management and the Role of Multidisciplinary Care

EP. 8: Role of IL-36 in GPP Pathogenesis and Treatment

EP. 9: Overview of Spesolimab for Management of GPP

EP. 10: Utilizing Intravenous and Subcutaneous Formulations of Spesolimab

Now Viewing

EP. 11: Future Directions for GPP Management and Key Takeaways

In your opinion, what is spesolimab’s place in therapy when treating GPP?
a. What unmet treatment needs remain, and what data would you like to see in the future?
What are some key takeaways or advice for other dermatologists who are managing patients with GPP?